Abstract
Crohn’s disease is a chronic, idiopathic condition characterized by intestinal inflammation and debilitating gastrointestinal symptomatology. Previous studies of inflammatory bowel disease (IBD), primarily in colitis, have shown reduced inflammation after electrical or pharmacological activation of the vagus nerve, but the scope and kinetics of this effect are incompletely understood. To investigate this, we studied the effect of electrical vagus nerve stimulation (VNS) in a rat model of indomethacin-induced small intestinal inflammation. 1 min of VNS significantly reduced small bowel total inflammatory lesion area [(mean ± SEM) sham: 124 ± 14 mm2, VNS: 62 ± 14 mm2, p = 0.002], intestinal peroxidation and chlorination rates, and intestinal and systemic pro-inflammatory cytokine levels as compared with sham-treated animals after 24 h following indomethacin administration. It was not known whether this observed reduction of inflammation after VNS in intestinal inflammation was mediated by direct innervation of the gut or if the signals are relayed through the spleen. To investigate this, we studied the VNS effect on the small bowel lesions of splenectomized rats and splenic nerve stimulation (SNS) in intact rats. We observed that VNS reduced small bowel inflammation also in splenectomized rats but SNS alone failed to significantly reduce small bowel lesion area. Interestingly, VNS significantly reduced small bowel lesion area for 48 h when indomethacin administration was delayed. Thus, 1 min of electrical activation of the vagus nerve reduced indomethacin-induced intestinal lesion area by a spleen-independent mechanism. The surprisingly long-lasting and spleen-independent effect of VNS on the intestinal response to indomethacin challenge has important implications on our understanding of neural control of intestinal inflammation and its potential translation to improved therapies for IBD.
Introduction
Crohn’s disease and ulcerative colitis are two debilitating inflammatory bowel diseases (IBD) characterized by abdominal pain, weight loss, and frequent bowel movements. The hallmarks of Crohn’s disease are the involvement of the small bowel and the transmural inflammation in contrast to ulcerative colitis, which is limited to the colon and presents as a more superficial intestinal inflammation with bloody stools. IBD often affects patients relatively early in life, commonly with onset between 15 and 30 years of age (; ). Many of the therapeutic options involve systemic immunosuppressive drugs with potential long-term adverse effects such as infections and malignancies (; ). A significant fraction of patients do not respond adequately to available treatment and approximately half of the people affected by Crohn’s disease still require abdominal surgery (). Accordingly, there is an unmet need to improve effective treatment of Crohn’s disease while minimizing risks of serious side effects. This is particularly important in young patients who will require years of immunosuppressive maintenance treatment to keep the disease in remission. Interestingly, there is increasing evidence that neural reflexes regulate gut inflammation in health and disease, suggesting that targeting neural circuits is a potential therapeutic option in IBD (; ).
The inflammatory reflex is an example of a neural circuit that involves signaling in the vagus nerve that regulates both organ-specific and systemic immune activity (; ; ). In the motor arc of this circuit, the vagus nerve, the splenic nerve, choline acetyltransferase (ChAT+)-expressing T cells, and alpha7 nicotinic acetylcholine receptors (α7 nAChR) on innate immune cells are essential for inhibition of systemic release of TNF-α in inflammation (; , ; ; ; ). The discovery and functional mapping of this reflex has supported progress to clinical trials of pharmacological or electrical activation of the inflammatory reflex for treatment of diseases characterized by excessive inflammation (; ; ; ; ; ).
In parallel to the spleen-dependent neural regulation of inflammation, a direct route to the gut has been proposed, in which efferent vagus nerve fibers functionally connect with the myenteric plexus in the intestinal wall (, ), referred to as the intestinal cholinergic anti-inflammatory pathway (). This pathway also inhibits release of pro-inflammatory cytokines from macrophages and other cells by cholinergic signals (; ; ).
There are many different animal models of IBD that recapitulate certain aspects of Crohn’s disease and ulcerative colitis, but none fully capture the complexity of either clinical disease (; ). An anti-inflammatory effect of vagus nerve stimulation (VNS) was observed in a number of studies of rodent colitis, such as DSS-, oxazolone-, and TNBS-colitis (; ; ; ; ) and others previously reviewed (). However, experimental data on VNS effect on lesions in the small bowel are largely lacking. This is important since nerve-mediated treatment mechanisms and effects may differ between anatomic regions and disease models (e.g., ulcerative colitis, Crohn’s disease, postoperative ileus) (). Whether the reduction of inflammation observed after VNS in intestinal inflammation is mediated by direct innervation of the gut or if the signals are relayed through the spleen is not completely understood (; ). Furthermore, the duration of VNS effects on reduction of intestinal inflammation is not known. A better understanding of the kinetics of VNS treatment on inflammatory lesions is important to inform both design of nerve stimulators and clinical trials in IBD (; ). Accordingly, we studied mechanism and kinetics of VNS in indomethacin-induced acute intestinal inflammation as a small bowel disease model.
Materials and Methods
Ethics Statement
This study and the experimental protocols were approved under #2010-008 by the Institutional Animal Care and Use Committee (IACUC; Manhasset, NY).
Animals
Male Sprague Dawley rats (6–8 weeks old) were obtained from Taconic Farms, Inc., (Hudson, NY) and the study was conducted at The Feinstein Institutes for Medical Research (FIMR; Manhasset, NY). Animal care including room, cage and equipment sanitation conformed to the guidelines cited in the Guide for the Care and Use of Laboratory Animals, and the applicable standard operating procedures of FIMR. Animals were housed in a laboratory environment with temperatures ranging between 19.5 and 24.5°C and relative humidity between 30 and 70%. Automatic timers provided 12 h of light and 12 h of dark. Animals were allowed access ad libitum to Harlan Teklad Rodent Chow (Denver, CO) and fresh municipal tap water. This study was approved by FIMR’s Institutional Animal Care and Use Committee.
Vagus Nerve Stimulation
The surgery and method used for VNS has been previously described (; ). The rats were anesthetized with a ketamine (100 mg/kg) and xylazine (10 mg/kg) intramuscular injection and secured in supine position. A ventral midline cervical incision was made between the mandible and sternum, and the subcutaneous tissue and salivary glands were bluntly separated and retracted laterally. The left cervical vagus nerve was isolated between the sternomastoid and sternohyoid muscles and secured with a custom-built bipolar cuff electrode (Microprobes, Gaithersburg, MD) with a silastic coated platinum-iridium wire lead. Sham stimulated rats were handled similarly but without electrical stimulation.
Stimulator (SetPoint Medical Corp., Valencia, CA)-driven charge-balanced biphasic pulses were generated using a bipolar current source and were capacitively isolated with > 1 uF ceramic capacitors on both electrode outputs. Rats were stimulated with a pulse waveform amplitude of 1 mA, 200 μs pulse width, and 50 μs inter-pulse-interval, previously demonstrated to activate vagus nerve fibers (), for 60 s at 10 Hz. Following electrical stimulation, the electrode was removed, and the incision sutured with 4–0 braided silk.
Splenic Nerve Stimulation
The surgery and method used for splenic nerve stimulation (SNS) has been previously described (). The rats were anesthetized and secured in a right lateral decubitus position. The spleen was carefully exposed through a 3 cm skin incision above the spleen, and the major splenic blood vessels were traced back to their convergence. The splenic nerve was isolated and suspended on a steel hook electrode (PlasticsOne, Roanoke, VA). Electrical SNS was performed with the same parameters as the VNS, 1 mA, 200 μs pulse width, and 50 μs inter-pulse-interval, for 60 s at 10 Hz. After stimulation, the hook electrode was removed, and the incision sutured in two layers with 4–0 braided silk. Sham SNS was performed by exposing the splenic nerve without electrode placement and electrical stimulation.
Vagus Nerve Stimulation in Splenectomized Rats
The rats were anesthetized and secured in supine position. A bipolar cuff electrode was secured around the left carotid sheath as described above. The rats were gently repositioned to a right lateral decubitus position and the spleen exposed by a 3 cm incision on the left abdomen above the spleen. The major splenic blood vessels were isolated, ligated with 4–0 silk suture, cut distally to the suture, and the spleen removed. The incision was subsequently sutured in two layers with 4–0 braided silk, and electrical or sham VNS was performed as described above.
Enteropathy Model
We used an enteropathy model known to produce lesions in the small intestine (; ; ; ). 0.5 h after VNS or sham procedure, the rats were injected subcutaneously on the back with 10 mg/kg indomethacin (5 mg/mL in 5% sodium bicarbonate) and returned to rack housing. For experiments evaluating the prolonged effect of VNS, indomethacin was injected either 0.5, 24, 48, or 72 h after the VNS or sham procedure. Evans Blue was administered intravenously under anesthesia (isoflurane; 3%) 0.5 h before euthanasia. Rats were euthanized by CO2 asphyxiation 24 h post induction of enteropathy. Blood was collected via cardiac puncture and clotted at room temperature for 1 h. The intestine from the proximal jejunum to the cecum was removed, cleaned, and formalin-fixed. The distal jejunum was assessed for histopathology.
For analysis of inflammatory mediators in the intestine and serum, Evans blue was withheld from a set of animals. In these animals, a standardized 2.54 cm section of the region between the distal jejunum and proximal half of ilium was cleaned, snap frozen in liquid nitrogen, and homogenized in a tissue protein extraction reagent (Pierce Biotechnology, Waltham, MA) containing a protease/phosphatase inhibitor cocktail (Roche, Basel, Switzerland). Lesion area in these rats was not quantitated.
Assessment of Enteropathy and Serum Assays
Fixed intestines were flat-mounted, photographed, and the total lesion area was quantitated by a blinded scorer using digital morphometry (Scion Image; Scion Corporation or ImageJ; NIH). Photomicrographs were acquired of fixed jejunal samples that were embedded in paraffin and stained with hematoxylin and eosin. Chlorination and peroxidation activity were determined using EnzChek Myeloperoxidase Activity Assay Kit (Invitrogen, Waltham, MA) according to the manufacturer’s instructions. Intestinal IL-23 normalized to protein and serum HMGB1 concentrations were measured by western blot. Serum TNF was measured by ELISA (R&D Systems, Minneapolis, MN). Concentrations of select other mediators of intestinal inflammation were measured by a quantitative multiplexed electrochemiluminescence assay (Rat Discovery Kit, Meso Scale Discovery, Rockville, MD).
Statistical Analysis
Differences in lesion areas between groups were analyzed by Student’s t-test or ANOVA with Bonferroni’s post hoc analysis. Hedges’ g was used to calculate effect size for Student’s t-test to measure magnitude of differences between groups1. Biomarker data was assumed to be normally distributed and Grubbs’ outlier test (α = 0.05) was used. Reduction from mean level of sham biomarkers in serum and tissue were analyzed with Student’s t-test. Data are shown as percentage of sham (mean ± SEM) unless otherwise specified and number of animals (n) are reported per group. p < 0.05 was considered significant. Statistical calculations were performed using the Prism 8 software (GraphPad software, San Diego, CA).
Results
Vagus Nerve Stimulation Reduced Small Bowel Inflammation in Indomethacin-Induced Enteropathy
Rats were subjected to cervical VNS or sham stimulation followed by subcutaneous injection of indomethacin. Small intestinal mucosal enteropathy was evaluated 24 h thereafter. Ulcers were observed almost exclusively in the distal portion of the small intestine (Figure 1A). Quantification by digital morphometric analysis showed a significantly smaller cumulative lesion area in the small intestine in VNS-treated animals as compared with sham ([mean lesion area ± SEM]: sham 124 ± 14 mm2, VNS: 62 ± 14 mm2, p < 0.002; effect size = 1.0) (Figure 1B). Microscopic analysis of ulcerated areas of the small intestine showed severe villus degradation (Figure 1C).
FIGURE 1
Myeloperoxidase (MPO) peroxidation activity, an established marker of neutrophil infiltration (), was significantly lower in VNS-treated as compared with sham-treated animals (Figures 1D,E). Peroxidation activity [Figure 1D; (RFU/min ± SEM) sham: 1,466 ± 439, VNS: 432 ± 142, p = 0.02; effect size = 1.3] and chlorination activity [Figure 1E; (RFU/min ± SEM) sham: 2,187 ± 342, VNS: 887 ± 402, p = 0.02; effect size = 1.3] were significantly reduced in VNS-treated compared with sham animals.
Serum TNF levels were significantly lower in VNS-treated rats compared with sham [(% of sham ± SEM) sham: 100 ± 16, VNS: 30 ± 8, p = 0.003; effect size = 2.2; Figure 2A]. Similarly, relative serum levels of the alarmin HMGB1 were significantly lower in VNS-treated animals as compared with sham animals [(% of sham ± SEM) sham: 100 ± 6, VNS: 53 ± 10, p = 0.0006; effect size = 2.3; Figure 2B and Supplementary Figure 1]. VNS-treated animals had significantly lower relative intestinal levels of IL-23 [(% of sham ± SEM) sham: 100 ± 17, VNS: 55 ± 16, p = 0.04; effect size = 0.9; Figure 3A and Supplementary Figure 1], IFN-γ, IL-1β, and IL-4 [(% of sham ± SEM) IFN-γ sham: 100 ± 27, VNS: 31 ± 11, p = 0.03; IL-1β sham: 100 ± 27, VNS: 31 ± 11, p = 0.03; IL-4 sham: 100 ± 34, VNS: 23 ± 11, p = 0.04; Figure 3B and Supplementary Table 1] as compared with sham. Mean relative levels of IL-5, KC, and TNF levels were lower, though not significant, in VNS vs. sham-treated animals [(% of sham ± SEM) IL-5 sham: 100 ± 21, VNS: 89 ± 37, p = 0.4; KC sham: 100 ± 36, VNS: 51 ± 15 p = 0.1; TNF sham: 100 ± 28, VNS: 55 ± 16, p = 0.1; Figure 3B and Supplementary Table 1]. IL-13-levels were at or below the lower limit of detection (2 pg/mL) and were not plotted.
FIGURE 2
FIGURE 3
Vagus Nerve Stimulation Effect on Small Bowel Inflammation Independent of Spleen
In certain contexts, the effects of VNS on cytokines and inflammation require the splenic nerve and an intact spleen (, ; ; ). To determine whether the spleen was required for the VNS effect in this model, a set of animals was splenectomized immediately before VNS and indomethacin administration. Lesions in the small intestine were quantified 24 h after injection. The cumulative lesion area in the small intestine was significantly lower in VNS-treated than in sham-treated animals also in the absence of the spleen [(mean lesion area ± SEM) sham: 88 ± 28 mm2, VNS: 15 ± 11 mm2, p = 0.02; effect size = 1.1; Figure 4A]. Furthermore, relative serum HMGB1 levels were significantly lower in VNS-treated as compared with sham-treated animals [(mean lesion area ± SEM) sham: 100 ± 11, VNS: 62 ± 11, p = 0.01; effect size 1.2; Figure 4B]. We first confirmed that SNS was effective in reducing endotoxin-induced serum TNF in this rat strain in an independent group of rats (). To determine whether SNS alone reduces indomethacin-induced ulcers in the small intestine, we performed electrical or sham SNS followed by indomethacin injection and measured intestinal lesion area 24 h later. We observed no significant difference in lesion area between animals treated with SNS or sham SNS [(lesion size in mm2 ± SEM) sham: 93 ± 13, SNS: 93 ± 22, p = 0.5; effect size = 0.01; Figure 4C]. In addition, SNS treated rats did not show significantly lower relative levels of serum HMGB1 levels [(% of sham ± SEM) sham: 100 ± 12, SNS: 153 ± 12, p > 0.9; effect size 1.3; Figure 4D]. Thus, SNS alone did not reduce small bowel lesion in indomethacin-induced enteropathy, nor was the spleen required for the protective effects of VNS in this model.
FIGURE 4
Protection Against Small Bowel Inflammation Sustained 48 h After Vagus Nerve Stimulation
In endotoxemia, a brief episode of stimulation, lasting seconds to minutes, has a sustained effect on the release of pro-inflammatory cytokines (; ). To investigate the duration of VNS effect on intestinal ulcer development in indomethacin-induced enteropathy, we performed VNS or sham surgery followed by a delayed induction of enteropathy, from 0.5 to 72 h. The area of intestinal ulceration was quantified at 24 h after indomethacin injection. We observed a significant decrease in intestinal lesion area when indomethacin was administered 0.5 or 24 h after VNS as compared with sham treatment [(lesion size in mm2 ± SEM) sham: 124 ± 14, 24 h post-VNS: 62 ± 14, p = 0.02; vs. 48 h post-VNS: 49 ± 10, p = 0.03; Figure 5]. In animals injected with indomethacin at 48 h or 72 h after VNS, there was no significant reduction in lesion area as compared with sham-treated animals [(lesion size in mm2 ± SEM) sham: 124 ± 14 vs. 72 h post-VNS: 130 ± 27, p > 0.9; vs. 96 h post-VNS: 108 ± 28, p > 0.9; Figure 5].
FIGURE 5
Discussion
Here, we found that electrical stimulation of the vagus nerve reduced indomethacin-induced acute small bowel inflammation by a spleen-independent mechanism. Reduction of small bowel lesioning remained for 48 h after a single episode of VNS.
The findings here that electrical VNS reduced small bowel inflammation align with previous studies that show that signals in the vagus nerve regulate levels of pro-inflammatory cytokines and inflammation in a wide range of organs and scenarios (). Reduction of the elevated levels of TNF that promote intestinal inflammation in Crohn’s disease has been a therapeutic success (). However, after 1 year of anti-TNF treatment, more than half of the patients have stopped the treatment due to inadequate response, loss of response, or intolerance (). Therefore, the additional evidence of vagus nerve regulation of intestinal lesion development provided here may be useful to support further development therapeutic modalities that target the neural regulation of inflammation.
The mechanism for vagus nerve regulation of intestinal inflammation is not fully understood. The vagus nerve directly innervates the gastrointestinal tract and is a key conduit for the bi-directional communication between the enteric nervous system and the central nervous system (). The main neurotransmitter of the vagus nerve is acetylcholine, known not only to regulate visceral functions such as gastrointestinal motility, but also the release of pro-inflammatory cytokines from innate immune cells (). Both afferent and efferent signals in the vagus nerve participate in the regulation of pro-inflammatory cytokines in inflammation (). Data from murine models suggest that the reflex control of gut inflammation is mediated by the efferent vagus nerve and sympathetic nerve signals that culminate in regulating the activity of macrophages that reside in the viscera where vagus innervation is abundant (; ; ; ; ).
Available data indicate that signals in the vagus nerve regulate gut inflammation by different routes, spleen-independent and spleen-dependent. One spleen-independent conduit involves the vagus nerve, efferent sympathetic nerves and myenteric efferent fibers that regulate macrophages in the intestinal wall (; ). Evidence of spleen-independent routes for vagus-nerve-mediated regulation of inflammation is also found in other visceral organs such as the pancreas: VNS reduced pancreatitis severity by a spleen-independent mechanism ().
A spleen-dependent route of vagus nerve regulation of inflammation is the inflammatory reflex, which involves efferent vagus neurons, the celiac ganglion, the splenic nerve, and the spleen (; ). These signals within the inflammatory reflex are propagated to immune cells in the spleen capable of biosynthesizing acetylcholine (). Both spleen-dependent and spleen-independent neural regulation of inflammation may reduce macrophage accumulation and release of pro-inflammatory cytokines in the gut through activation of α7 nAChR, α4β2 nAChR or other cholinergic receptors (; ; , ; ; ). Of note, ChAT+ T cells, capable of acetylcholine biosynthesis, are found in the innervated Peyer’s patches of the small intestine of rodents (; ; ) and it is possible that these cells partake in local regulation of immune cell activity as has been observed in spleen (). Considering this, the finding here that the spleen is not essential for VNS-mediated reduction of disease intensity in indomethacin-induced small bowel inflammation is important. The data imply that for treatment of inflammatory lesions in IBD with involvement of the small intestine, targeting the cervical or gut-directed subdiaphragmatic vagus may be superior to targeting the splenic nerve or spleen.
The observation here that VNS reduced small intestinal inflammation for up to 48 h aligns with our previous finding that VNS reduced systemic TNF release in endotoxemia for up to 48 h (; ) and offers support for refining therapeutic stimulation protocols. The first published clinical trial using VNS for treatment of Crohn’s disease in biologic-naïve subjects was designed using the stimulation “duty cycle” (time on vs. time off) originally designed to treat epilepsy, stimulating up to 262 times per day (). The findings here regarding the persistence of protection in the small bowel enabled a once per day VNS treatment in biologic-experienced subjects with Crohn’s disease (). The growing mechanistic insights on regional differences in the neural regulation of inflammation between and within organs such as the colon, the small bowel, and other visceral organs, will be valuable for design of future IBD trials using bioelectronic medicine.
An interesting molecule in persistent inflammation is the alarmin HMGB1, which is involved in or associated with the pathogenesis of many inflammatory diseases and regulated by cholinergic signals (; ). HMGB1 is a “late mediator” of inflammation, and excessive levels of HMGB1 may be involved in sustaining inflammation, with associated inflammatory tissue damage, organ dysfunction, and cognitive impairment (; ; ). Of note, anti-HMGB1 therapy was effective in significantly reducing disease severity even when administered days after onset of severe inflammation (), and anti-HMGB1 antibodies and HMGB1-targeted sorption beads have a protective effect in experimental intestinal inflammation (; ; ). Based on that knowledge, it will be interesting to consider whether the link between VNS and reduced HMGB1 levels may help explain how VNS may be effective in reducing not only inflammation onset, but also ongoing inflammation (; ). Accordingly, our observation here that VNS reduced serum levels of HMGB1 along with molecular markers of inflammation in the gut and small bowel lesion area is noteworthy. The potential role of HMGB1 in IBD is being further explored () and a pathogenetic role has been proposed for HMGB1-dependent TLR4 activation in indomethacin-induced small intestinal damage (). The available data supports further consideration and study of the vagus nerve regulation of HMGB1, its potential as a biomarker and therapeutic target in IBD ().
The current study, using a rat indomethacin-induced enteropathy model, provides evidence that electrical activation of the cervical vagus nerve reduces inflammatory lesions in the small bowel, a pathology that is commonly a critical part of the pathogenesis in Crohn’s disease (). The rodent models of colitis that have previously been used to study vagus nerve and α7 nAChR-mediated regulation of disease severity are by many considered more relevant to ulcerative colitis than to Crohn’s disease (; ; ; ). In humans, previous surgical vagotomy was associated with later development of Crohn’s disease, but not ulcerative colitis (), suggesting that vagus nerve regulation of inflammation may be more important in small bowel inflammation than in colitis, although this remains to be comprehensively studied.
As described above, the first published study of VNS for the treatment of Crohn’s disease used high duty cycle nerve stimulation (; ). While no major safety concerns were reported, higher frequency and intensity of electrical nerve stimulation consume more energy, thus requiring greater battery capacity for implanted stimulators. Furthering our understanding of the VNS parameter requirements for clinical benefit can therefore allow for optimization of device design and stimulation protocols. Longer periods between stimulations may also reduce patient discomfort both by limiting the stimulation-associated laryngeal muscle contraction and temporary voice changes as well as enabling smaller devices that are easier to implant and maintain (,). Therefore, the observation that a short VNS period of 60 s was followed by a prolonged anti-inflammatory effect provides important information for the development of future clinical therapeutics.
Conclusion
Electrical stimulation of the vagus nerve, but not of the splenic nerve, reduced indomethacin-induced small intestinal enteropathy for up to 2 days. The spleen was not required for the effect of VNS on small bowel lesion area. These observations are an important step toward better understanding of the mechanisms of vagus nerve regulation of inflammation in diseases with engagement of the small bowel.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
This study and the experimental protocols were approved under #2010-008 by the Institutional Animal Care and Use Committee (IACUC; Manhasset, NY).
Author contributions
AC, AD, and YL planned and performed experiments. AC, AD, YL, ME, and PO analyzed and interpreted data. AC, YL, PO, and ME wrote the manuscript. All authors edited the manuscript.
Funding
This work was supported by SetPoint Medical, Inc. ME was supported by the Bengt Ihre Research Fellowship and Stockholm County Council ALF (project no. 20180565). AC and PO were supported by MedTechLabs, Stockholm.
Conflict of interest
YL is an employee of SetPoint Medical, Inc. AC and AD were employees of SetPoint Medical, Inc. at the time of data collection. Aside from co-author affiliation, this funder was not involved in the study design, data analyses, data interpretation, and the writing of the report. ME has received honoraria for lectures and consultancy from AbbVie, Merck (MSD), Takeda, Ferring, Orion Pharma, Otsuka, Tillotts, Novartis, Pfizer, and Janssen, received research funding from AbbVie and MSD, and has been a former shareholder of Emune AB. These funders were not involved in the study design, data analyses, data interpretation, and the writing of the report. PO has received honoraria for lectures from Ferring and Janssen and is a shareholder of Emune AB. AC and PO were supported by MedTechLabs, Stockholm. These funders were not involved in the study design, data analyses, data interpretation, and the writing of the report.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnins.2021.730407/full#supplementary-material
Supplementary Figure 1VNS reduced IL-23 and HMGB1 in small bowel inflammation. Representative densitometry from western blot of (A) serum HMGB1 and (B) intestinal IL-23. Mean quantified integrated intensity (IKK count) of HMGB1 in the sham group was 0.69. Mean quantified integrated intensity (IKK count) of IL-23/Actin in the sham group was 0.25.
Supplementary Table 1VNS reduced levels of select cytokines in indomethacin-induced enteropathy. Levels of select cytokines were measured by quantitative multiplexed electrochemiluminescence assay and normalized to the mean sham level. Data is presented as mean ± SEM. * p < 0.05 vs. sham.
Footnotes
References
1
AnderssonU.TraceyK. J. (2011). HMGB1 is a therapeutic target for sterile inflammation and infection.Annu. Rev. Immunol.29139–162. 10.1146/annurev-immunol-030409-101323
2
AnderssonU.WangH.PalmbladK.AvebergerA. C.BloomO.Erlandsson-HarrisH.et al (2000). High mobility group 1 protein (HMGB1) stimulates proinflammatory cytokine synthesis in human monocytes.J. Exp. Med.192565–570. 10.1084/jem.192.4.565
3
AnthonyA.PounderR. E.DhillonA. P.WakefieldA. J. (2000). Similarities between ileal Crohn’s disease and indomethacin experimental jejunal ulcers in the rat.Aliment Pharmacol. Ther.14241–245. 10.1046/j.1365-2036.2000.00694.x
4
BaiA.GuoY.LuN. (2007). The effect of the cholinergic anti-inflammatory pathway on experimental colitis.Scand. J. Immunol.66538–545. 10.1111/j.1365-3083.2007.02011.x
5
BerthoudH. R.CarlsonN. R.PowleyT. L. (1991). Topography of efferent vagal innervation of the rat gastrointestinal tract.Am. J. Physiol.260(1 Pt 2), R200–R207. 10.1152/ajpregu.1991.260.1.R200
6
BerthoudH. R.JedrzejewskaA.PowleyT. L. (1990). Simultaneous labeling of vagal innervation of the gut and afferent projections from the visceral forebrain with dil injected into the dorsal vagal complex in the rat.J. Comp. Neurol.30165–79. 10.1002/cne.903010107
7
BonazB.SinnigerV.HoffmannD.ClarençonD.MathieuN.DantzerC.et al (2016). Chronic vagus nerve stimulation in Crohn’s disease: a 6-month follow-up pilot study.Neurogastroenterol. Motil.28948–953. 10.1111/nmo.12792
8
BorovikovaL. V.IvanovaS.ZhangM.YangH.BotchkinaG. I.WatkinsL. R.et al (2000). Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin.Nature405458–462. 10.1038/35013070
9
BruckE.LasselinJ.Hicus study group, AnderssonU.SackeyP. V.OlofssonP. S.et al (2020). Prolonged elevation of plasma HMGB1 is associated with cognitive impairment in intensive care unit survivors.Intensive Care Med.46811–812. 10.1007/s00134-020-05941-7
10
CailottoC.Gomez-PinillaP. J.CostesL. M.van der VlietJ.Di GiovangiulioM.NemethovaA.et al (2014). Neuro-anatomical evidence indicating indirect modulation of macrophages by vagal efferents in the intestine but not in the spleen.PLoS One9:e87785. 10.1371/journal.pone.0087785
11
CaravacaA. S.GallinaA. L.TarnawskiL.TraceyK. J.PavlovV. A.LevineY. A.et al (2019). An effective method for acute vagus nerve stimulation in experimental inflammation.Front. Neurosci.13:877. 10.3389/fnins.2019.00877
12
Consolim-ColomboF. M.SangaletiC. T.CostaF. O.MoraisT. L.LopesH. F.MottaJ. M.et al (2017). Galantamine alleviates inflammation and insulin resistance in patients with metabolic syndrome in a randomized trial.JCI Insight.2:e93340. 10.1172/jci.insight.93340
13
CostantiniT. W.KrzyzaniakM.CheadleG. A.PutnamJ. G.HagenyA. M.LopezN.et al (2012). Targeting alpha-7 nicotinic acetylcholine receptor in the enteric nervous system: a cholinergic agonist prevents gut barrier failure after severe burn injury.Am. J. Pathol.181478–486. 10.1016/j.ajpath.2012.04.005
14
D’HaensG.CabrijanZ.EberhardsonM.van den BerghR.LöwenbergM.FiorinoG.et al (2018). The effects of vagus nerve stimulation in biologic-refractory Crohn’s disease: a prospective clinical trial.J. Crohn’s Colitis12S397–S398.
15
de JongeW. J.van der ZandenE. P.TheF. O.BijlsmaM. F.van WesterlooD. J.BenninkR. J.et al (2005). Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway.Nat. Immunol.68844–851. 10.1038/ni1229
16
De SimoneB.DaviesJ.ChouillardE.Di SaverioS.HoentjenF.TarasconiA.et al (2021). WSES-AAST guidelines: management of inflammatory bowel disease in the emergency setting.World J. Emergency Surg. BioMed. Central161–27. 10.1186/s13017-021-00362-3
17
Del SoldatoP.FoschiD.VarinL.DaniottiS. (1985). Indomethacin-induced intestinal ulcers in rats: effects of salicylazosulfapyridine and dexamethasone.Agents Actions16393–396. 10.1007/BF01982878
18
DhawanS.De PalmaG.WillemzeR. A.HilbersF. W.VerseijdenC.LuyerM. D.et al (2016). Acetylcholine-producing T cells in the intestine regulate antimicrobial peptide expression and microbial diversity.Am. J. Physiol. Gastrointest Liver Physiol.311G920–G933. 10.1152/ajpgi.00114.2016
19
DignassA.LindsayJ. O.SturmA.WindsorA.ColombelJ. F.AllezM.et al (2012). Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management.J. Crohns Colitis.6991–1030. 10.1016/j.crohns.2012.09.002
20
EberhardsonM.TarnawskiL.CentaM.OlofssonP. S. (2020). Neural control of inflammation: bioelectronic medicine in treatment of chronic inflammatory disease.Cold Spring Harb. Perspect. Med.10:a034181. 10.1101/cshperspect.a034181
21
GalitovskiyV.QianJ.ChernyavskyA. I.MarchenkoS.GindiV.EdwardsR. A.et al (2011). Cytokine-induced alterations of alpha7 nicotinic receptor in colonic CD4 T cells mediate dichotomous response to nicotine in murine models of Th1/Th17- versus Th2-mediated colitis.J. Immunol.1872677–2687. 10.4049/jimmunol.1002711
22
GenoveseM. C.GaylisN. B.SikesD.KivitzA.Lewis HorowitzD.PeterfyC.et al (2020). Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomised pilot study.Lancet Rheumatol.2e527–e538.
23
GhiaJ. E.BlennerhassettP.Kumar-OndiveeranH.VerduE. F.CollinsS. M. (2006). The vagus nerve: a tonic inhibitory influence associated with inflammatory bowel disease in a murine model.Gastroenterology1311122–1130. 10.1053/j.gastro.2006.08.016
24
GhiaJ. E.ParkA. J.BlennerhassettP.KhanW. I.CollinsS. M. (2011). Adoptive transfer of macrophage from mice with depression-like behavior enhances susceptibility to colitis.Inflamm. Bowel Dis.171474–1489. 10.1002/ibd.21531
25
GomollónF.DignassA.AnneseV.TilgH.Van AsscheG.LindsayJ. O.et al (2017). 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: Part 1: diagnosis and medical management.J. Crohn’s Colitis113–25. 10.1093/ecco-jcc/jjw168
26
GoverseG.StakenborgM.MatteoliG. (2016). The intestinal cholinergic anti-inflammatory pathway.J. Physiol.5945771–5780. 10.1113/jp271537
27
HanauerS. B.SandbornW. J.RutgeertsP.FedorakR. N.LukasM.MacIntoshD.et al (2006). Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial.Gastroenterology130323–333. 10.1053/j.gastro.2005.11.030
28
HustonJ. M.Gallowitsch-PuertaM.OchaniM.OchaniK.YuanR.Rosas-BallinaM.et al (2007). Transcutaneous vagus nerve stimulation reduces serum high mobility group box 1 levels and improves survival in murine sepsis.Crit. Care Med.352762–2768. 10.1097/01.CCM.0000288102.15975.BA
29
JiH.RabbiM. F.LabisB.PavlovV. A.TraceyK. J.GhiaJ. E. (2014). Central cholinergic activation of a vagus nerve-to-spleen circuit alleviates experimental colitis.Mucosal Immunol.7335–347. 10.1038/mi.2013.52
30
JuZ.ChavanS. S.AntoineD. J.DanchoM.TsaavaT.LiJ.et al (2014). Sequestering HMGB1 via DNA-conjugated beads ameliorates murine colitis.PLoS One9:e103992. 10.1371/journal.pone.0103992
31
KentT. H.CardelliR. M.StamlerF. W. (1969). Small intestinal ulcers and intestinal flora in rats given indomethacin.Am. J. Pathol.54237–249.
32
KieslerP.FussI. J.StroberW. (2001). Experimental models of inflammatory bowel diseases. medecine et hygiene.Cell Mol Gastroenterol. Hepatol.59241–248.
33
KoopmanF. A.ChavanS. S.MiljkoS.GrazioS.SokolovicS.SchuurmanP. R.et al (2016). Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis.Proc. Natl. Acad. Sci. U S A.1138284–8289. 10.1073/pnas.1605635113
34
KresselA. M.TsaavaT.LevineY. A.ChangE. H.AddorisioM. E.ChangQ.et al (2020). Identification of a brainstem locus that inhibits tumor necrosis factor.Proc. Natl. Acad. Sci. U S A.11729803–29810. 10.1073/pnas.2008213117
35
LevineY. A.FaltysM.ZitnikR. (2018a). Activation of the inflammatory reflex in rheumatoid arthritis and inflammatory bowel disease; preclinical evidence.Neuromodulation20181493–1502.
36
LevineY. A.SimonJ.FaltysM. (2018b). “Neurophysiologic and chronic safety testing of a miniaturized active implanted device with integrated electrodes for bioelectronic medicine applications,” in Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society, EMBS (Piscataway, NJ: Institute of Electrical and Electronics Engineers Inc). 10.1109/EMBC.2018.8513061
37
LevineY. A.SimonJ.FaltysM.ZitnikR. (2018c). “Chapter 127 - bioelectronic therapy for the treatment of rheumatoid arthritis and inflammatory bowel disease,” in Neuromodulation, 2nd Edn, edsKramesE. S.PeckhamP. H.RezaiA. R. (Cambridge, MA: Academic Press).
38
LiuB.WandersA.WirdefeldtK.SjolanderA.SachsM. C.EberhardsonM.et al (2020). Vagotomy and subsequent risk of inflammatory bowel disease: a nationwide register-based matched cohort study.Aliment Pharmacol. Ther.511022–1030. 10.1111/apt.15715
39
LuckeyA.LivingstonE.TacheY. (2003). Mechanisms and treatment of postoperative ileus.Arch. Surg.138206–214. 10.1001/archsurg.138.2.206
40
MaedaS.HikibaY.ShibataW.OhmaeT.YanaiA.OguraK.et al (2007). Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer.Biochem. Biophys. Res. Commun.360394–400. 10.1016/j.bbrc.2007.06.065
41
MatteoliG.Gomez-PinillaP. J.NemethovaA.Di GiovangiulioM.CailottoC.van BreeS. H.et al (2014). A distinct vagal anti-inflammatory pathway modulates intestinal muscularis resident macrophages independent of the spleen.Gut63938–948. 10.1136/gutjnl-2013-304676
42
MeregnaniJ.ClarençonD.VivierM.PeinnequinA.MouretC.SinnigerV.et al (2011). Anti-inflammatory effect of vagus nerve stimulation in a rat model of inflammatory bowel disease.Auton Neurosci.16082–89. 10.1016/j.autneu.2010.10.007
43
MeroniE.StakenborgN.Gomez-PinillaP. J.StakenborgM.Aguilera-LizarragaJ.FlorensM.et al (2021). Vagus nerve stimulation promotes epithelial proliferation and controls colon monocyte infiltration during DSS-induced colitis.Front. Med.8:987. 10.3389/fmed.2021.694268
44
MizoguchiA. (2012). Animal models of inflammatory bowel disease. in: progress in molecular biology and translational science.Prog. Mol. Biol. Transl. Sci.105263–320. 10.1016/B978-0-12-394596-9.00009-3
45
NadataniY.WatanabeT.TanigawaT.MachidaH.OkazakiH.YamagamiH.et al (2012). High mobility group box 1 promotes small intestinal damage induced by nonsteroidal anti-inflammatory drugs through Toll-like receptor 4.Am. J. Pathol.18198–110. 10.1016/j.ajpath.2012.03.039
46
OlofssonP. S.BoutonC. (2019). Bioelectronic medicine: an unexpected path to new therapies.J. Int. Med.286237–239. 10.1111/joim.12967
47
OlofssonP. S.LevineY. A.CaravacaA.ChavanS. S.PavlovV. A.FaltysM.et al (2015). Single-pulse and unidirectional electrical activation of the cervical vagus nerve reduces TNF in endotoxemia.Bioelectron. Med.237–42.
48
OlofssonP. S.Rosas-BallinaM.LevineY. A.TraceyK. J. (2012). Rethinking inflammation: neural circuits in the regulation of immunity.Immunol. Rev.248188–204. 10.1111/j.1600-065X.2012.01138.x
49
PaloneF.VitaliR.CucchiaraS.MenniniM.ArmuzziA.PuglieseD.et al (2016). Fecal HMGB1 reveals microscopic inflammation in adult and pediatric patients with inflammatory bowel disease in clinical and endoscopic remission.Inflamm. Bowel Dis.222886–2893. 10.1097/MIB.0000000000000938
50
PayneS. C.FurnessJ. B.StebbingM. J. (2019). Bioelectric neuromodulation for gastrointestinal disorders: effectiveness and mechanisms.Nat. Rev. Gastroenterol. Hepatol.1689–105. 10.1038/s41575-018-0078-6
51
PozzoliC.MenozziA.GrandiD.SolenghiE.OssiprandiM. C.ZullianC.et al (2007). Protective effects of proton pump inhibitors against indomethacin-induced lesions in the rat small intestine.Naunyn Schmiedebergs Arch. Pharmacol.374283–291. 10.1007/s00210-006-0121-y
52
PrechtlJ. C.PowleyT. L. (1990). The fiber composition of the abdominal vagus of the rat.Anat. Embryol.181101–115. 10.1007/BF00198950
53
RodaG.JharapB.NeerajN.ColombelJ. F. (2016). Loss of response to Anti-TNFs: definition, epidemiology, and management. clinical and translational gastroenterology.Am. College Gastroenterol.7:e135. 10.1038/ctg.2015.63
54
Rosas-BallinaM.OchaniM.ParrishW. R.OchaniK.HarrisY. T.HustonJ. M.et al (2008). Splenic nerve is required for cholinergic antiinflammatory pathway control of TNF in endotoxemia.Proc. Natl. Acad. Sci. U S A.10511008–11013. 10.1073/pnas.0803237105
55
Rosas-BallinaM.OlofssonP. S.OchaniM.Valdes-FerrerS. I.LevineY. A.ReardonC.et al (2011). Acetylcholine-Synthesizing T cells relay neural signals in a vagus nerve circuit.Science33498–101. 10.1126/science.1209985
56
SinnigerV.PellissierS.FauvelleF.TrocméC.HoffmannD.VercueilL.et al (2020). A 12-month pilot study outcomes of vagus nerve stimulation in Crohn’s disease.Neurogastroenterol. Motil.32:e13911. 10.1111/nmo.13911
57
SnoekS. A.VerstegeM. I.van der ZandenE. P.DeeksN.BulmerD. C.SkynnerM.et al (2010). Selective alpha7 nicotinic acetylcholine receptor agonists worsen disease in experimental colitis.Br. J. Pharmacol.160322–333. 10.1111/j.1476-5381.2010.00699.x
58
StakenborgN.BoeckxstaensG. E. (2021). Bioelectronics in the brain-gut axis: focus on inflammatory bowel disease (IBD).Int. Immunol.33337–348. 10.1093/intimm/dxab014
59
SteinbergB. E.SundmanE.TerrandoN.ErikssonL. I.OlofssonP. S. (2016). Neural control of inflammation.Anesthesiology1241174–1189.
60
TarnawskiL.ReardonC.CaravacaA. S.Rosas-BallinaM.TuscheM. W.DrakeA. R.et al (2018). Adenylyl cyclase 6 mediates inhibition of TNF in the inflammatory reflex.Front. Immunol.9:2648. 10.3389/fimmu.2018.02648
61
TorresJ.BonovasS.DohertyG.KucharzikT.GisbertJ. P.RaineT.et al (2019). ECCO guidelines on therapeutics in Crohn’s disease: medical treatment.J. Crohn’s Colitis144–22. 10.1093/ecco-jcc/jjz180
62
Valdes-FerrerS. I.PapoinJ.DanchoM. E.OlofssonP. S.LiJ.LiptonJ. M.et al (2016). HMGB1 mediates anemia of inflammation in murine sepsis survivors.Mol. Med.21951–958. 10.2119/molmed.2015.00243
63
van der ZandenE. P.SnoekS. A.HeinsbroekS. E.StanisorO. I.VerseijdenC.BoeckxstaensG. E.et al (2009). Vagus nerve activity augments intestinal macrophage phagocytosis via nicotinic acetylcholine receptor alpha4beta2.Gastroenterology1371029-39, 1039.e1-4. 10.1053/j.gastro.2009.04.057
64
VulchanovaL.CaseyM. A.CrabbG. W.KennedyW. R.BrownD. R. (2007). Anatomical evidence for enteric neuroimmune interactions in Peyer’s patches.J. Neuroimmunol.18564–74. 10.1016/j.jneuroim.2007.01.014
65
WangH.YuM.OchaniM.AmellaC. A.TanovicM.SusarlaS.et al (2003). Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation.Nature421384–388. 10.1038/nature01339
66
WillemzeR. A.BrinkmanD. J.WeltingO.van HamersveldP. H. P. P.VerseijdenC.LuyerM. D.et al (2019). Acetylcholine-producing T cells augment innate immune-driven colitis but are redundant in T cell-driven colitis.Am. J. Physiol. Gastrointest Liver Physiol.317G557–G568. 10.1152/ajpgi.00067.2019
67
YamadaT.DeitchE.SpecianR. D.PerryM. A.SartorR. B.GrishamM. B. (1993). Mechanisms of acute and chronic intestinal inflammation induced by indomethacin.Inflammation17641–662. 10.1007/BF00920471
68
YangR.MikiK.OksalaN.NakaoA.LindgrenL.KilleenM. E.et al (2009). Bile high-mobility group box 1 contributes to gut barrier dysfunction in experimental endotoxemia.Am. J. Physiol. Regul. Integr. Comp. Physiol.297R362–R369. 10.1152/ajpregu.00184.2009
69
YapJ. Y. Y.KeatchC.LambertE.WoodsW.StoddartP. R.KamenevaT. (2020). Critical review of transcutaneous vagus nerve stimulation: challenges for translation to clinical practice.Front. Neurosci.14:284. 10.3389/fnins.2020.00284
70
ZhangL.WuZ.TongZ.YaoQ.WangZ.LiW. (2021). Vagus nerve stimulation decreases pancreatitis severity in mice.Front. Immunol.11:595957. 10.3389/fimmu.2020.595957
Summary
Keywords
Crohn’s disease, inflammatory reflex, vagus nerve stimulation, small bowel, indomethacin, cholinergic anti-inflammatory pathway, bioelectronic medicine, inflammatory bowel disease
Citation
Caravaca AS, Levine YA, Drake A, Eberhardson M and Olofsson PS (2022) Vagus Nerve Stimulation Reduces Indomethacin-Induced Small Bowel Inflammation. Front. Neurosci. 15:730407. doi: 10.3389/fnins.2021.730407
Received
24 June 2021
Accepted
16 December 2021
Published
12 January 2022
Volume
15 - 2021
Edited by
Vitor Engracia Valenti, São Paulo State University, Brazil
Reviewed by
Bruno Bonaz, Centre Hospitalier Universitaire de Grenoble, France; Pedro Gomez, Catholic University of Louvain, Belgium
Updates
Copyright
© 2022 Caravaca, Levine, Drake, Eberhardson and Olofsson.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: April S. Caravaca, april.caravaca@ki.seYaakov A. Levine, ylevine@setpointmedical.com
†These authors have contributed equally to this work
This article was submitted to Autonomic Neuroscience, a section of the journal Frontiers in Neuroscience
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.